Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant Gastroenterologist at the Royal Free Hospital. He has clinical expertise in ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling ...

The American College of Lifestyle Medicine (ACLM) has published the first clinical practice guideline to put lifestyle ...

The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

New research shows how metabolic activity and thus the communication between intestinal tissue and microbiome collapses ...

Welcome to the realm of irritable bowel syndrome (IBS), a prevalent and chronic disorder that affects over 1 billion ...